Boan Biotech's BA1202 Approved for Clinical Trial
- Written by PR Newswire
-The First Novel CEA/CD3 Bispecific Antibody in China-
YANTAI, China, May 16, 2023 /PRNewswire/ -- Boan Biotech announced today that its BA1202, a CEACAM5 (CEA)/CD3 bispecific antibody, has been approved for a clinical trial by the Center for Drug Evaluation of China's National Medical Products Administration (NMPA). BA1202 is the first CEA/CD3...
Read more: Boan Biotech's BA1202 Approved for Clinical Trial














